艾迪药业
(688488)
| 流通市值：62.19亿 | | | 总市值：62.19亿 |
| 流通股本：4.21亿 | | | 总股本：4.21亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 92,893,957 | 411,363,846.09 | 301,557,240.33 | 238,740,738.87 |
| 营业收入 | 92,893,957 | 411,363,846.09 | 301,557,240.33 | 238,740,738.87 |
| 二、营业总成本 | 120,441,962.65 | 500,619,778.22 | 357,787,517.04 | 262,359,746.18 |
| 营业成本 | 53,840,179.09 | 221,336,169.05 | 158,661,968.24 | 124,183,538.16 |
| 税金及附加 | 919,245.06 | 5,949,366.28 | 4,839,704.83 | 3,470,058.39 |
| 销售费用 | 21,191,476.67 | 104,416,740.08 | 73,383,251.44 | 50,845,905.62 |
| 管理费用 | 23,235,084.08 | 95,276,664.09 | 72,283,479.86 | 49,997,962.13 |
| 研发费用 | 17,748,750.48 | 63,182,425.19 | 41,414,637.17 | 29,743,921.63 |
| 财务费用 | 3,507,227.27 | 10,458,413.53 | 7,204,475.5 | 4,118,360.25 |
| 其中:利息费用 | 3,896,316.78 | 11,763,788.71 | 8,208,191.57 | 4,772,068.64 |
| 其中:利息收入 | 404,926.71 | 1,488,733.01 | 1,001,692.12 | 580,603.13 |
| 加:公允价值变动收益 | 3,108,562.43 | 1,543,801.73 | 3,945,573.28 | 7,625,633.7 |
| 加:投资收益 | 7,573,963 | 12,615,093.88 | 14,479,356.43 | 10,682,870.21 |
| 资产处置收益 | - | 70,406.82 | 70,406.82 | 69,344.87 |
| 资产减值损失(新) | -46,975.56 | -23,670,065.67 | -6,568,844.22 | -7,154,909.58 |
| 信用减值损失(新) | -1,519,146.91 | -3,732,918.09 | -2,555,826.11 | -5,681,930.03 |
| 其他收益 | 1,571,082.13 | 10,381,697.83 | 6,625,397.5 | 5,259,597.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -16,860,520.56 | -92,047,915.63 | -40,234,213.01 | -12,818,400.3 |
| 加:营业外收入 | 4,752.83 | 140,204.06 | 103,788.11 | 93,591.38 |
| 减:营业外支出 | 27,947.91 | 177,288.67 | 138,084.25 | 114,484.25 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -16,883,715.64 | -92,085,000.24 | -40,268,509.15 | -12,839,293.17 |
| 减:所得税费用 | -3,276,826.29 | -16,015,462 | -7,810,282.82 | -3,239,365.98 |
| 六、净利润 | -13,606,889.35 | -76,069,538.24 | -32,458,226.34 | -9,599,927.19 |
| 持续经营净利润 | -13,606,889.35 | -76,069,538.24 | -32,458,226.34 | -9,599,927.19 |
| 归属于母公司股东的净利润 | -13,606,889.35 | -76,069,538.24 | -32,458,226.34 | -9,599,927.19 |
| (一)基本每股收益 | -0.03 | -0.18 | -0.08 | -0.02 |
| (二)稀释每股收益 | -0.03 | -0.18 | -0.08 | -0.02 |
| 八、其他综合收益 | - | -302,154.12 | -302,154.12 | -255,745.7 |
| 归属于母公司股东的其他综合收益 | - | -302,154.12 | -302,154.12 | -255,745.7 |
| 九、综合收益总额 | -13,606,889.35 | -76,371,692.36 | -32,760,380.46 | -9,855,672.89 |
| 归属于母公司股东的综合收益总额 | -13,606,889.35 | -76,371,692.36 | -32,760,380.46 | -9,855,672.89 |
| 公告日期 | 2024-04-26 | 2024-04-16 | 2023-10-28 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |